The role of echocardiographic parameters in the prevention and monitoring of cardiac toxicity on antitumor treatments
DOI:
https://doi.org/10.52692/1857-0011.2023.1-75.18Keywords:
cardiac toxicity, heart failure, echocardiographic prognosisAbstract
The paper presents a summary of the literature that includes the results of the research on the echocardiographic parameters for the early detection and monitoring of the cardiac toxicity of the antitumor treatment. While the left ventricular ejection fraction is currently the most widely used index to quantify cardiac function in cardio-oncology, there are a number of indices under investigation to prove their prognostic value in the occurrence of adverse cardiac events during cancer therapy. Such indices derived from the Doppler method, speckle tracking parameters, strain rate as well as parameters derived from three-dimensional echocardiography, which can provide additional sensitivity and substantial prognostic value for future cardiovascular events.
References
Lee Chuy K, Yu AF. Cardiotoxicity of Contemporary Breast Cancer Treatments. Curr Treat Options Oncol. 2019 May 9; 20(6):51.
Thandra, K.C., Barsouk, A., Saginala, K., Padala S.A., et.al. Epidemiology of Non-Hodgkin’s Lymphoma. Med. Sci. 2021; 9:5.
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68, 394–424.
Sibo Tian, Kim M. Hirshfield, Salma K. Jabbour, Deborah Toppmeyer, Bruce G. Haffty, Atif J. Khan, and Sharad Goyal. Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Front Oncol. 2014; 4: 277.
Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102–11.
Juan Carlos Plana, Maurizio Galderisi, Ana Barac, Michael S. Ewer, Bonnie Ky, Marielle Scherrer-Crosbie. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging, Volume 15, Issue 10, 1 October 2014, Pages 1063–1093.
John V. McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J. Malcolm Walker, and Derek M. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017; 31(1): 63–75.
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022; 43:280–299.
Alexander R Lyon, Teresa López-Fernández, Liam S Couch, Riccardo Asteggiano, et.al., ESC Scientific Document Group, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC), European Heart Journal, 2022; 43 (41):4243–4244.
Marijke Linschoten, Janine A M Kamphuis, Anna van Rhenen et. al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. The Lancet Haematology 2020; 7 (4): e295–e308.
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022; 43:280–299.
Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology. 2010;28:3422–8.
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol. 2006; 48:2258–62.
de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). Journal of Clinical Oncology. 2014; 20; 45 –46
Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2–overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. American Society of Clinical Oncology. 2005; 23:7811–9.
Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002; 86 (11):1697–1700.
Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13(5):699–709.
Shah AM, Solomon SD. Myocardial deformation imaging: current status and future directions. Circulation. 2012; 125:e244–8.
Solomon SD, Anavekar N, Skali H, McMurray JV, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112:3738–44.
Altena R, Perik PJ, van Veldhuisen DJ, de Vries EGE, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncology. Elsevier Ltd; 2009 (10): 391–9.
Khan AA, Ashraf A, Singh R, Rahim A, Rostom W, Hussain M, Renner I, Collins NJ. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity. Intern Med J. 2017; 47:104–109.
Prajith Jeyaprakash, Sukhmandeep Sangha, Katherine Ellenberger, Shanthosh Sivapathan, Faraz Pathan and Kazuaki Negishi. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta‐Analysis of Placebo Arms From Randomized Controlled Trials. Journal of the American Heart Association. 2021;10:e018802.
Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504–1524.
Verdonschot JA, Merken JJ, Brunner-La Rocca HP, Hazebroek MR, Eurlings C, Thijssen E, Wang P, Weerts J, van Empel V, Schummers G, Schreckenberg M, van den Wijngaard A, Lumens J, Brunner HG, Heymans SR, Krapels IP, Knackstedt C. Value of speckle tracking-based deformation analysis in screening relatives of patients with asymptomatic dilated cardiomyopathy. JACC Cardiovasc Imaging 2020;13:549–558.
Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol 2019;108:355–365.
Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging 2017; 18:392–40.
Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S, Trimarco B, Lancellotti P, Arpino G, Galderisi M. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging 2019; 20:1345–1352.
Negishi T, Thavendiranathan P, Negishi K, Marwick TH; SUCCOUR Investigators. Rationale and design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: the SUCCOUR Trial. JACC Cardiovasc Imaging 2018; 11:1098–1105.
Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, Plappert T, Englefield V, Smith AM, Zhang C, Hundley WG, Ky B. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. JACC Cardiovasc Imaging 2018; 11:1059–1068.
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 2019; 4:1007–1018.
Upshaw J.N., Finkelman B., Hubbard R.A., Smith A.M., Narayan H.K., Arndt L., Domchek S., DeMichele A., Fox K., Shah P., et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. Pt 2JACC Cardiovasc. Imaging. 2020;13:198–210.
Mincu RI, Lampe LF, Mahabadi AA, Kimmig R, Rassaf T, Totzeck M. Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease-A Meta-Analysis. J Clin Med. 2021;10(17):3890.
Reema T, Boddicker N, Martinez J, et. al. Evaluating Diastolic Function by Echocardiography in a Prospective Cohort of Patients with Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL) Who Received Anthracycline-Based Chemotherapy. Circulation. 2021; 144:A10607.
Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., Agler D.A., Badano L.P., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2014;27:911–939.
Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F., 3rd, Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An. Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2016; 17:1321–1360.
Desai MY, Windecker S, Lancellotti P, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019; 74(7):905 – 927.
Negishi T, Miyazaki S, Negishi K. Echocardiography and cardio-oncology. Heart Lung Circ. 2019; 28(9):1331 – 1338.
Negishi T, Miyazaki S, Negishi K. Echocardiography and cardio-oncology. Heart Lung Circ. 2019; 28(9):1331 – 1338.
Quintana RA, Bui LP, Moudgil R, et al. Speckle-tracking echocardiography in cardio-oncology and beyond. Tex Heart Inst J. 2020; 47(2):96 – 107.
Khouri MG, Ky B, Dunn G, et al. Echocardiography core laboratory reproducibility of cardiac safety assessments in cardio-oncology. J Am Soc Echocardiogr. 2018; 31(3):361 – 371.e3.
Lenihan, Daniel, J. et al. The Washington Manual of Cardio-Oncology. Available from: Wolters Kluwer, Wolters Kluwer Health, 2021; 8 – 16.
Downloads
Published
License
Copyright (c) 2023 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
